News
01/06/2023
Maria Asimopoulos
Lecanemab is the second drug targeting the underlying pathophysiology of Alzheimer disease to receive approval.
Lecanemab is the second drug targeting the underlying pathophysiology of Alzheimer disease to receive approval.
Lecanemab is the second drug...
01/06/2023
First Report Managed Care